摘要
目的:探讨复方丹参滴丸在糖尿病肾病(DN)治疗中的应用价值,并分析其对DN患者血超敏C反应蛋白(hs-CRP)、P选择素、转化生长因子-β1(TGF-β1)的影响。方法:将120例DN患者随机分为两组,每组60例。以接受常规药物治疗者为对照组,以在常规治疗的基础上联合应用复方丹参滴丸治疗者为治疗组,所有患者均治疗16周。对比两组治疗过程中血糖水平、胰岛素水平、肾脏功能、hs-CRP、P选择素及TGF-β1的变化情况。结果:在16周的治疗过程中,两组FPG、HbA1c、Scr、BUN、24 h mAlb、hs-CRP、P选择素及TGF-β1均呈降低趋势,FIN呈升高趋势(P<0.05);同时在完成治疗8周及16周后,治疗组FPG、HbA1c、Scr、BUN、24 h mAlb、hs-CRP、P选择素及TGF-β1均低于对照组,FIN高于对照组,比较差异均有统计学意义(P<0.05)。而两组间治疗不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:复方丹参滴丸可有效改善DN患者hs-CRP、P选择素及TGF-β1水平,在DN的治疗中具有良好的应用效果。
Objective:To investigate the application value of compound danshen drop pills in the treatment of diabetic nephropathy(DN),and to analyze its effect on blood hypersensitive c-reactive protein(hs-CRP),P-selectin and transforming growth factor-β1(TGF-β1)in patients with DN.Method:The total of 120 patients with DN were randomly divided into two groups,60 patients in each group.The control group was given routine drug treatment,the treatment group was treated with Compound Danshen Drop Pills on the basis of routine treatment.All patients were treated for 16 weeks.The changes of blood glucose level,insulin level,renal function,hs-CRP,P-selectin and TGF-β1 in the two groups were compared.Result:In the process of 16 weeks of treatment,two groups of FPG,HbA1c,Scr,BUN,24 h mAlb,hs-CRP,P-selectin and TGF-β1 all showed a trend of decrease,FIN showed a trend of increase(P<0.05),and after 8 weeks and 16 weeks treatment,the treatment group of FPG,HbA1c,Scr,BUN,24 h mAlb,hs-CRP,P-selectin and TGF-β1 were lower than the control group,FIN was higher than the control group,with statistical difference(P<0.05).However,there was no statistical difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Compound Danshen Drop Pills can effectively improve the levels of hs-CRP,P-selectin and TGF-β1 in patients with DN,and have a good application effect in the treatment of DN.
作者
刘君海
陈晓铭
LIU Junhai;CHEN Xiaoming(The Second Affiliated Hospital of Guangdong Medical University(the Second People’s Hospital of Zhanjiang City),Zhanjiang 524003,China;不详)
出处
《中国医学创新》
CAS
2020年第7期127-131,共5页
Medical Innovation of China
基金
广东省湛江市科技计划项目(2014B101)。